Protection Against Beta-Amyloid-Induced Synaptic And Memory Impairments Via Altering Beta-Amyloid Assembly By Bis(Heptyl)-Cognitin

Lan Chang,Wei Cui,Yong Yang,Shujun Xu,Wenhua Zhou,Hongjun Fu,Shengquan Hu,Shinghung Mak,Juwei Hu,Qin Wang,Victor Pui-Yan Ma,Tony Chung-Lit Choi,Edmond Dik-Lung Ma,Liang Tao,Yuanping Pang,Michael J. Rowan,Roger Anwyl,Yifan Han,Qinwen Wang
DOI: https://doi.org/10.1038/srep10256
IF: 4.6
2015-01-01
Scientific Reports
Abstract:beta-amyloid (A beta) oligomers have been closely implicated in the pathogenesis of Alzheimer's disease (AD). We found, for the first time, that bis(heptyl)-cognitin, a novel dimeric acetylcholinesterase (AChE) inhibitor derived from tacrine, prevented A beta oligomers-induced inhibition of long-term potentiation (LTP) at concentrations that did not interfere with normal LTP. Bis(heptyl)-cognitin also prevented A beta oligomers-induced synaptotoxicity in primary hippocampal neurons. In contrast, tacrine and donepezil, typical AChE inhibitors, could not prevent synaptic impairments in these models, indicating that the modification of A beta oligomers toxicity by bis(heptyl)-cognitin might be attributed to a mechanism other than AChE inhibition. Studies by using dot blotting, immunoblotting, circular dichroism spectroscopy, and transmission electron microscopy have shown that bis(heptyl)-cognitin altered A beta assembly via directly inhibiting A beta oligomers formation and reducing the amount of preformed A beta oligomers. Molecular docking analysis further suggested that bis(heptyl)-cognitin presumably interacted with the hydrophobic pockets of A beta, which confers stabilizing powers and assembly alteration effects on A beta. Most importantly, bis(heptyl)-cognitin significantly reduced cognitive impairments induced by intra-hippocampal infusion of A beta oligomers in mice. These results clearly demonstrated how dimeric agents prevent A beta oligomers-induced synaptic and memory impairments, and offered a strong support for the beneficial therapeutic effects of bis(heptyl)-cognitin in the treatment of AD.
What problem does this paper attempt to address?